- Client: Lek Pharmaceuticals
- Date: 2006-2007
- Location: U.S. District Court for the Southern District of New York
In the Omeprazole patent litigation Schiff Hardin represented Lek Pharmaceuticals, a subsidiary of Sandoz and Novartis, in its successful defense of AstraZeneca's patent infringement action regarding the plaintiff's Prilosec® product.
After a 42-day trial, in a 368-page opinion the Southern District of New York found that Lek's product did not infringe AstraZeneca's patent rights.
In re Omeprazole Patent Litigation (490 F.Supp.2d 381)